AcademicArticleSCO_84997470980

abstract

• © 2016 Sociedad Mexicana de Oftalmología Purpose To compare the efficacy of topical diclofenac 0.1% vs topical nepafenac in reducing pain associated to argon laser retinal photocoagulation Material and methods Double blinded, randomized clinical trial. One hundred thirty two patients with diagnosis of proliferative diabetic retinopathy treated with retinal photocoagulation. Randomization in to 2 groups: topical diclofenac and nepafenac. Before retinal photocoagulation 2 doses of topical non-steroidal anti-inflammatory drugs were applied, pain was assessed immediately and 15 minutes after. Level of pain, adverse effects and associated symptoms at the end of retinal photocoagulation were analyzed. Results The median for age in both groups was 55 years, M:F ratio of 1:1.4. The immediate level of pain was 35.5 (ICR 14-72) for nepafenac and 45 (ICR 14-70) for diclofenac (P = .48). At 15 minutes the pain level was 30 (ICR 4-50) for nepafenac and 20 (ICR 2-50) for diclofenac. There was no difference in associated symptoms or adverse effects among groups. Conclusions The preventive treatment with topical nepafenac and diclofenac is equally effective and safe for reducing the pain associated with retinal photocoagulation in patients with proliferative diabetic retinopathy.